Can a common supplement fight chemo brain? new trial aims to find out
NCT ID NCT04520139
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will take NAC or a placebo. The trial has two phases: first to find the safest dose, then to see if it helps thinking and memory.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-Acetyl-Cysteine (NAC)
What this could lead to
If it works, this could point toward a way to prevent or reduce 'chemo brain' in ovarian cancer patients receiving platinum-based chemotherapy.
What could go wrong
This is an early-phase trial (phase 1/2) with only 102 participants, so results may not apply broadly. NAC may not improve cognitive symptoms and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact